DEDICATED TO CURING NEUROENDOCRINE CANCER
MAY 2016

HANS CLEVERS NAMED INAUGURAL LAUREN T. ERB LECTURER FOR HIS WORK ON ORGANOIDS

At a recent invitation-only NETRF event which convened researchers from around the world, we were pleased to name Hans Clevers, MD, PhD as the inaugural Lauren T. Erb Lecturer. This Lecture was established to honor NETRF's former Director of Research Lauren Erb for her decade of dedicated service to NETRF. "I am very honored by the lecture and that Hans Clevers was named as the first lecturer," said Lauren Erb. "The bar has been set very high and I look forward to attending future lectures."

Dr. Clevers is a professor of molecular genetics at the University Utrecht in The Netherlands. He was the former president of the Royal Netherlands Academy of Arts & Sciences as well as the former director of the Hubrecht Institute. Dr. Clevers is known as a leading stem cell researcher and for being the first person to identify intestinal stem cells. Dr. Clevers was chosen as the recipient of the Lauren T. Erb Lecture for his work on organoids and their potential in cancer therapy development.

2016 LOS ANGELES NEUROENDOCRINE TUMOR PATIENT & CAREGIVER CONFERENCE

Saturday, June 25th
8:30am - 4:30pm
Cedars-Sinai Medical Center
Samuel Oschin Comprehensive Cancer Institute

Learn from prominent NET experts about research updates, biomarkers, PRRT, GA68 Imaging, carcinoid syndrome, surgery, liver directed therapies, nutrition and more. Hear patients discuss their NET journeys and experiences and take advantage of the many networking opportunities. See the list of conference speakers.
DEADLINE APPROACHING FOR NANETS INVESTIGATOR AWARD

In collaboration with the North American Neuroendocrine Tumor Society (NANETS), NETRF is funding a Basic/Translational Science Investigator Award (BTSI), made possible through the generous support of the Margie and Robert E. Petersen Foundation.  The purpose of this award is to encourage scientists at the end of their fellowship or beginning of their faculty appointment to pursue basic and/or translational research focused on NETs. This is a two year award and will provide $50,000 in funding each year.  For more information on the BTSI Award, to see application criteria, and to apply, visit https://www.nanets.net/btsi16. Applications will be reviewed by a committee led by the NANETS research chairs and presented to the NANETS Board of Directors for final vote and approval. Deadline for submission of the application is June 13, 2016.
FDA GRANTS PRIORITY REVIEW OF NEW DRUG APPLICATION TO TREAT CARCINOID SYNDROME

Lexicon Pharmaceuticals today announced that the FDA has granted priority review for Telotristat Etiprate, a drug used for the treatment of carcinoid syndrome. Priority Review means that the FDA has a goal to take action on an application within six months, putting a tentative release date at the end of 2016. In August, positive top-line results were reported for their pivotal phase 3 Telotristat Etiprate study in patients with carcinoid syndrome. In March, a New Drug Application was submitted to the FDA, seeking approval for the marketing and sale of Telotristat Etiprate, an oral drug which showed benefits in patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy. Chair of NANETS Matthew H. Kulke, MD presented the findings of the Phase 3 trial at the 2015 NANETS Neuroendocrine Tumor Symposium.
Ron Hollander and members of the Prospect Transportation family at the the Walk with Chuck event
Members of the Prospect Transportation family at the Walk with Chuck event
WALK WITH CHUCK RAISES AWARENESS AND FUNDS FOR NET RESEARCH

Prospect Transportation and Alternative Fuels Transportation hosted their Annual Walk With Chuck event in May. This 10-mile walk through Bergen County honored the memory of Charlie Eichholz.  Since 2012, Prospect Transportation has registered over 400 walkers for its annual springtime walk where money raised supports the NET Research Foundation. Thank you to all the participants and supporters.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded over $12 million in research projects. Your support enables the NET Research Foundation to make rapid progress toward discovering a cure for neuroendocrine cancers. We are grateful to you for your generosity.

NVS logo
We are pleased to announce that this eUpdate is supported by Novartis Pharmaceutical Corporation.
The mission of the Neuroendocrine Tumor Research Foundation is to fund research to discover cures and more effective treatments for carcinoid, pancreatic, and related neuroendocrine cancers.

NETRF is a 501(c)(3) organization. All contributions are tax-deductible to the extent allowed by law. 
To learn more, view our  Audited Financial Statements  and  IRS Form 990 .